MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS
Author(s): ,
Marta Martín-Izquierdo
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Félix López-Cadenas
Affiliations:
Hematology,Hospital Universitario de Salamanca,Salamanca,Spain
,
Javier Sánchez del Real
Affiliations:
Hematology,Hospital Universitario de León,León,Spain
,
Alberto Hernández-Sánchez
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Jesús M Hernández-Sánchez
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Kamila Janusz
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Eva Lumbreras
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
María Díez-Campelo
Affiliations:
Hematology,Hospital Universitario de Salamanca,Salamanca,Spain
,
Mar Tormo
Affiliations:
Hematology,Hospital Clínico Universitario de Valencia e Instituto de investigación INCLIVA,Valencia,Spain
,
Marta Megido
Affiliations:
Hematology,Hospital del Bierzo,Ponferrada, León,Spain
,
Carmen Olivier
Affiliations:
Hematology,Hospital General de Segovia,Segovia,Spain
,
Andrés Madinaveitia-Ochoa
Affiliations:
Hematology,Hospital Universitario Miguel Servet,Zaragoza,Spain
,
Guillermo Martín-Nuñez
Affiliations:
Hematology,Hospital Virgen del Puerto,Plasencia,Spain
,
Julio Dávila
Affiliations:
Hematology,Hospital Nuestra Señora de Sónsoles,Ávila,Spain
,
Carlos Aguilar
Affiliations:
Hematology,Hospital Santa Bárbara,Soria,Spain
,
Juan Nicolás Rodríguez
Affiliations:
Hematology,Hospital Juan Ramón Jiménez,Huelva,Spain
,
José M Alonso
Affiliations:
Hematology,Hospital Río Carrión,Palencia,Spain
,
Magdalena Sierra
Affiliations:
Hematology,Hospital Virgen de la Concha,Zamora,Spain
,
Manuel Vargas
Affiliations:
Hematology,Hospital del Jarrio,Asturias,Spain
,
Sandra Santos-Mínguez
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Cristina Miguel-García
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Rocío Benito
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
,
Jesús María Hernández-Rivas
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain;Hematology,Hospital Universitario de Salamanca,Salamanca,Spain
,
Fernando Ramos
Affiliations:
Hematology,Hospital Universitario de León,León,Spain
María Abáigar
Affiliations:
Hematology; Hospital Universitario de Salamanca,Centro de Investigación del Cáncer de Salamanca,Salamanca,Spain
EHA Library. Martín Izquierdo M. Jun 14, 2019; 266333; PF533
Ms. Marta Martín Izquierdo
Ms. Marta Martín Izquierdo
Contributions
×
Abstract

Abstract: PF533

Type: Poster Pitch

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background
Mutations in cohesin complex genes have been described commonly in several types of cancer, with an incidence of 8% in myeloid diseases and myelodysplastic syndromes (MDS), and have been linked to marrow fibrosis by our group in a prior publication (Ramos F et al. Oncotarget 2016). However, their clinical impact is still undetermined.

Aims
To identify mutations in cohesin complex genes in MDS patients by next generation sequencing (NGS) and to analyze their implications at clinical level (correlation with clinical characteristics and outcome).

Methods
A cohort of 850 myeloid samples was analyzed by targeted deep sequencing (Nextera Rapid Capture Custom Enrichment) using an Illumina ® custom panel of 117 myeloid-related genes, including cohesin complex genes: STAG1, STAG2, SMC1A, SMC3 and RAD21. A final selection of 324 patients with clinical, biological and follow-up data were selected.

Results

The median age was 75 years (p10-p90: 57-84); 59% were male. According to the WHO 2008 classification most of the patients had RCMD (40%), and RAEB 1-2 (30%), while 11% had a MDS associated with isolated del(5q), and the remaining subtypes RCUD, RARS, U-MDS were observed in less than 10% each. Regarding IPSS-R, the majority of patients had very low (27%) and low (44%) risk, with 85% of the series having normal karyotype or clonal alterations of very good or good risk. The median follow-up was 2.5 years (range 0.01-15.6) and during this time 50% of patients died and 30% progressed to acute myeloid leukemia (AML).

NGS study identified a 9.3% of patients with mutations in cohesin complex genes: STAG2 (6.5%), SMC3 (1.5%) and SMC1A (1.2%). In the global cohort, mutations in cohesin genes were associated with RAEB-1 and RAEB-2 subtypes (p=0.003), intermediate IPSS-R (p=0.010), intermediate cytogenetic risk (p=0.026) and a lower platelet count (p=0.004). In addition, cohesin-mutated patients showed a shorter overall survival (3 vs. 5 years, p=0.06). Moreover, mutations in these genes were associated with a higher rate of progression to AML (p=0.004) and a shorter time to AML progression (1.5 vs. 9.1 years, p<0.001).

To further study the negative impact of these mutations, analyses were carried out for each IPSS-R groups, separately. Interestingly, in low IPSS-R patients, these analyses showed that cohesin mutations were the sole factor significantly associated with an earlier progression to AML (p<0.001), while hemoglobin, platelet and neutrophil count, blasts in bone marrow and cytogenetic were not related to the outcome (Table 1). In addition, in the multivariate analysis, the presence of cohesin mutations was associated with a shorter overall survival in this subgroup of patients (HR=0.291 (95% CI, 0.113-0.752); p=0.011) (Table 2).

Conclusion
Mutations in cohesin complex genes (mainly STAG2) are associated with a worse prognosis due to a higher rate of AML evolution and a shorter time to progression to AML in the global cohort. Of note, mutations in the cohesin complex were associated with a potential prognostic impact in low risk IPSS-R subgroup. Therefore, analysis of these mutations, especially in this subgroup of patients, should be carried out.

Session topic: 9. Myelodysplastic syndromes - Biology & Translational Research

Keyword(s): Clinical outcome, Mutation analysis, Myelodysplasia, Progression

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies